MYCN and neuroblastoma: As for its potential clinical application, Chipumuro et al. found cyclin-dependent kinase 7 (CDK7) inhibitor, THZ1, selectively downregulates SE-regulated MYCN overexpression and MYCN-driven transcription amplification in neuroblastoma (91).